Royal Marsden NHS Foundation Trust
J&J’s Erleada prostate cancer study shows significant reduction in risk of metastasis
Erleada plus hormone therapy significantly improved key short- and long-term clinical outcomes
Major prostate cancer screening trial launched in UK
The £42m Transform trial will recruit men aged 50-74, with a lower age limit of 45 for some men
Pfizer/Astellas share positive overall survival results for Xtandi in prostate cancer
Around 55,100 cases of prostate cancer are diagnosed in the UK every year
Novartis’ Pluvicto granted FDA approval for expanded prostate cancer use
The authorisation approximately triples the number of patients eligible to receive the therapy
ICR researchers uncover genes responsible for tumour progression in prostate cancer
The findings could pave the way for new treatment approaches that improve patient outcomes
Prostate cancer blood test with ‘unprecedented accuracy’ cuts biopsies by 50%
There is currently no national screening programme for prostate cancer in the UK
ICR study reveals how PARP inhibitor resistance develops in prostate cancer patients
The research could pave the way for the development of new drugs that prevent drug resistance
AstraZeneca announces positive results for Truqap in phase 3 prostate cancer study
More than 52,000 cases of prostate cancer are diagnosed in the UK every year
ICR researchers identify potential treatment approach for acute myeloid leukaemia
More than 3,100 people are diagnosed with the aggressive blood cancer in the UK every year
Pfizer shares positive phase 3 results for Talzenna combination in prostate cancer
Up to 20% of patients will develop metastatic castration-resistant disease within five to seven years of diagnosis
J&J’s Erleada shows overall survival benefit in head-to-head prostate cancer study
Approximately 300,000 new cases of the disease are diagnosed in the US every year
ICR researchers reveal benefits of personalised radiotherapy for bladder cancer patients
More than 130,000 patients are treated with radiotherapy on the NHS every year